Aliskiren-treated type 2 diabetes patients with comorbid kidney or heart disease did not show lower rates of heart attack, stroke or death from cardiovascular and renal disease-related causes at 2.5 years compared with the placebo group, a study indicated. Aliskiren treatment was linked to lower systolic and diastolic blood pressures and higher average decreases in urinary albumin-to-creatinine ratio, but increased incidence of hyperkalemia and hypotension, compared with placebo therapy. The results were presented at Kidney Week 2012 and published in the New England Journal of Medicine.

Related Summaries